Physician profile
Opal A Baker
NPI 1346904026
$1,576.73
in general payments reported to CMS, 2019-2025
13 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $128 · 2024: $165 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $378.21 | 2025 | Carvykti, Rybrevant |
| Emd Serono, INC. | $218.25 | 2023-2024 | Bavencio |
| Astellas Pharma US INC | $159.24 | 2025 | Padcev, Vyloy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.33 | 2025 | |
| Daiichi Sankyo INC. | $148.21 | 2024-2025 | Injectafer, Enhertu |
| Incyte Corporation | $124.24 | 2025 | Monjuvi |
| Glaxosmithkline, LLC. | $117.85 | 2025 | Ojjaara |
| Pharmaessentia USA Corporation | $115.99 | 2025 | Besremi |
| Astrazeneca Pharmaceuticals LP | $53.66 | 2025 | Tagrisso, Calquence |
| Rigel Pharmaceuticals, INC. | $42.88 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Novartis Pharmaceuticals Corporation | $32.01 | 2023 | |
| Lilly USA, LLC | $20.24 | 2024 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $17.62 | 2025 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Opal Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.